Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza

Influenza and other Respiratory Viruses

Volumn 2, Issue 4, 2008, Pages 115-125

  Goy, Kylie ^a   Bibra, Sally Von ^a   Lewis, Jenny ^a   Laurie, Karen ^b   Barr, Ian ^b   Anderson, David ^a   Hellard, Margaret ^a   Ffrench, Rosemary ^a,c  

^a BURNET INSTITUTE   (Australia)

^b WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^c NONE   (Australia)

Author keywords

Cytokines; Haemagglutinin; Heterosubtypic; Human; T cell; Vaccination

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FLUVAX; GAMMA INTERFERON; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; AVIAN INFLUENZA; CELL TYPE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLUENZA VIRUS A H5N1; MALE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIGENS, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MIDDLE AGED; T-LYMPHOCYTES; YOUNG ADULT;

EID: 65249148471     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2008.00046.x     Document Type: Article

References (51)

1. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerging Infect Dis 2006; 12:48-54.
2. Cox RJ, Brokstad KA, Ogra P. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004; 59:1-15.
3. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. Heterologous protection against lethal A / HongKong / 156 / 97 (H5N1) influenza virus infection in C57BL / 6 mice. J Gen Virol 2000; 81:2689-2696.
4. Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 1997; 186:2063-2068.
5. Epstein SL, Kong W-P, Misplon JA et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005; 23:5404-5410.
6. Sambhara S, Kurichh A, Miranda R et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001; 211:143-153.
7. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001; 75:5141-5150.
8. Effros RB, Doherty PC, Gerhard W, Bennink J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 1977; 145:557-568.
9. Fu T-M, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Protective cellular immunity: Cytotoxic T lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol 1997; 71:2715-2721.
10. Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 1998; 72:8682-8689.
11. Sterkers G, Michon J, Henin Y, Gomard E, Hannoun C, Levy JP. Fine specificity analysis of human influenza-specific cloned cell lines. Cell Immunol 1985; 94:394-405.
12. Gioia C, Castilletti C, Tempestilli M et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerging Infect Dis 2008; 14:121-128.
13. Jameson J, Cruz J, Terajima M, Ennis FA. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999; 162:7578-7583.
14. Seo SH, Webster RG. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001; 75:2516-2525.
15. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194:159-167.
16. Lipatov AS, Hoffmann E, Salomon R, Yen H-L, Webster RG. Crossprotectiveness and immunogenicity of influenza A / Duck / Singapore / 3 / 97(H5) vaccines against infection with A / Vietnam / 1203 / 04(H5N1) virus in ferrets. J Infect Dis 2006; 194:1040-1043.
17. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerging Infect Dis 2005; 11:201-209.
18. Bui H-H, Peters B, Assarsson E, Mbawuike I, Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. PNAS 2007; 104:246-251.
19. Scherle PA, Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. J Exp Med 1986; 164:1114-1128.
20. Scherle PA, Gerhard W. Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo. PNAS 1988; 85:4446-4450.
21. Bresson J-L, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A / Vietnam / 1194 / 2004 (H5N1) vaccine: Phase I randomised trial. Lancet 2006; 367:1657-1664.
22. Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A phase I randomised control trial. Lancet 2006; 368:991-997.
23. Stephenson I, Nicholson KG, Gluck R et al. Safety and antigenicity of whole virus and subunit influenza A / Hong Kong / 1073 / 99 (H9N2) vaccine in healthy adults: Phase I randomised trial. Lancet 2003; 362:1959-1966.
24. Cox JH, Ferrari G, Janetzki S. Measurement of cytokine release at the single cell level using the ELISPOT assay. Methods 2006; 38:274-282.
25. Chapman TJ, Castrucci MR, Padrick RC, Bradley LM, Topham DJ. Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection. Virology 2005; 340:296-306.
26. Hu N, D'Souza C, Cheung H, Lang H, Cheuk E, Chamberlain JW. Highly conserved pattern of recognition of influenza A wild-type and variant CD8+ CTL epitopes in HLA-A2+ humans and transgenic HLA-A2+ H2 class I-deficient mice. Vaccine 2005; 23:5231-5244.
27. Riberdy JM, Flynn KJ, Stech J, Webster RG, Altman JD, Doherty PC. Protection against a lethal avian influenza A virus in a mammalian system. J Virol 1999; 73:1453-1459.
28. Avetisyan G, Ragnavolgyi E, Toth GT, Hassan M, Ljungman P. Cellmediated immune responses to influenza vaccination in healthy volunteers and allogneic stem cell transplant recipients. Bone Marrow Transplant 2005; 36:411-415.
29. Centre for Disease Control (CDC). Concepts and Procedures for laboratory-based influenza surveillance. U.S. Department of Health, Public Health Service, Atlanta, Georgia: 1982.
30. Tannock GA, Paul JA, Herd R et al. Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection. J Clin Microbiol 1989; 27:524-528.
31. Booy R, Brown LE, Grohmann GS, MacIntyre CR. Pandemic vaccines: Promises and pitfalls. Med J Aust 2006; 185:S62-S65.
32. Mitchell DM, Callard RE. Fine specificity of the in vitro antibody response to influenza virus by human blood lymphocytes. J Immunol 1983; 131:1229-1233.
33. Quinnan GV, Ennis FA, Tuazon CU et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980; 30:362-369.
34. Tamura M, Webster RG, Ennis FA. Subtype cross-reactive, infectionenhancing antibody responses to influenza A viruses. J Virol 1994; 68:3499-3504.
35. Sandbulte MR, Jimenez GS, Boon ACM, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:265-272.
36. Murphy BR, Phelan MA, Nelson DL et al. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981; 13:554-560.
37. Burlington DB, Wright PF, van Wyke KL, Phelan MA, Mayner RE, Murphy BR. Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol 1985; 21:847-849.
38. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-943.
39. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-1351.
40. Beare AS, Webster RG. Replication of avian influenza viruses in humans. Arch Virol 1991; 2:37-42.
41. Profeta ML, Palladino G. Serological evidence of human infections with avian influenza viruses. Brief report. Arch Virol 1986; 4:355-360.
42. Lu X, Edwards LE, Desheva JA et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 10:44-46.
43. Quan F-S, Huang C, Compans RW, Kang S-M. Virus-like particle vaccine induces protective immunity against homolous and heterologous strains of influenza virus. J Virol 2007; 81:3514-3524.
44. Sasaki S, Jaimes MC, Holmes TH et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2006; 81:215-228.
45. World Health Organisation Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerging Infect Dis 2005; 11:1515-1521.
46. Ennis FA, Cruz J, Jameson J, Klein M, Burt M, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999; 259:256-261.
47. Holtz KM, Anderson DK, Cox MMJ. Production of a recombinant influenza vaccine using the baculovirus expression vector system. Bioprocess J 2005; 2:65-73.
48. Gao W, Soloff AC, Lu X et al. Protection of mice and poultry from lethal H5N1 influenza virus through adenovirus-based immunization. J Virol 2006; 80:1959-1964.
49. Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral- vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367:475-481.
50. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007; 25:2984-2989.
51. Kistner O, Howard MK, Spruth M et al. Cell culture (vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028-6036.